impact factor
logo
 

Full Papers

 

Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis


1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15

 

  1. Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Germany.
  2. Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin; and German Rheumatism Research Center (Deutsches Rheumaforschungszentrum, DRFZ), Berlin, Germany.
  3. Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin; and German Rheumatism Research Center (Deutsches Rheumaforschungszentrum, DRFZ), Berlin, Germany.
  4. Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin; German Rheumatism Research Center (Deutsches Rheumaforschungszentrum, DRFZ); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Berlin, Germany.
  5. Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Germany.
  6. Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Germany.
  7. Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Germany.
  8. Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin; and German Rheumatism Research Center (Deutsches Rheumaforschungszentrum, DRFZ), Berlin, Germany.
  9. Sleep Medicine Center, Charité-Universitätsmedizin Berlin, Germany.
  10. Sleep Medicine Center, Charité-Universitätsmedizin Berlin, Germany.
  11. Medical Director Global Innovative Pharma, Pfizer Pharma GmbH, Berlin, Germany.
  12. pj statistics, Berlin, Germany.
  13. Laboratory of Experimental Rheumatology and Neuroendocrino-Immunology, Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany.
  14. Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Germany.
  15. Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Germany.

CER8896
2016 Vol.34, N°5
PI 0848, PF 0856
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 27385076 [PubMed]

Received: 24/08/2015
Accepted : 08/02/2016
In Press: 22/06/2016
Published: 16/09/2016

Abstract

OBJECTIVES:
To compare sleep quality, disease activity and patient-reported outcomes such as fatigue and immune parameters in patients with rheumatoid arthritis treated with etanercept (ETA) or methotrexate (MTX).
METHODS:
Of 36 patients (28-joint Disease Activity Score, DAS28CRP≥3.2) in this 16-week (w), open, prospective study, 19 (11 women) received MTX 12.5–17 mg/w, and 17 (14 women) received ETA 25 mg x 2/w, alone or in combination with MTX. Clinical (DAS28CRP, visual analogue scale), laboratory (C-reactive protein [CRP]), sleep (polysomnography), functional (Multidimensional Fatigue Inventory; Health Assessment Questionnaire-Disability Index (HAQ-DI); 36-item Short-Form Health Survey (SF-36), immunological (humoral/cellular) and neuroendocrine (hormonal) parameters were recorded at baseline (BL), w8 and w16.
RESULTS:
BL characteristics did not differ significantly between the ETA and MTX groups except disease duration: mean age (years): 48.6±8.8 vs. 49.4±16.6; mean disease duration (months): 19.6±46.3 vs. 81.2±79.2; and DAS28CRP: 4.4±0.9 vs. 4.4±1.7, respectively. DAS28CRP, SF-36, and HAQ-DI improved significantly in both groups from BL to w16 (p≤0.05). The DAS28CRP improvements at w16 (mean changes -1.8 in the ETA group, and -1.4 in MTX group), were not statistically significant from each other. The absolute values of sleep efficiency, total sleep time, and stage 2 sleep duration increased significantly in the ETA group, but no significant changes were reported in the MTX group.
CONCLUSIONS:
Both therapies improved disease activity, CRP, SF-36 and HAQ-DI, with faster, more pronounced changes in DAS28CRP in the ETA group, which alone had significantly improved sleep parameters.

Rheumatology Article

Rheumatology Addendum